H. Lundbeck A/S's latest marketcap:

About H. Lundbeck A/S

H. Lundbeck A/S is a global pharmaceutical company specializing in the research, development, manufacturing, and commercialization of treatments for psychiatric and neurological disorders. Headquartered in Valby, Denmark, the company operates across Europe, the United States, and international markets.

Key Products

• Abilify Maintena/Abilify Asimtufii – For schizophrenia and bipolar I disorder in adults.
• Brintellix/Trintellix – Treats depressive disorders.
• Rexulti/Rxulti – Used for major depressive disorder and schizophrenia.
• Vyepti – Prevents migraines.
• Cipralex/Lexapro – Addresses depression.
• Northera – Treats symptomatic neurogenic orthostatic hypotension.
• Onfi – For epilepsy.
• Sabril – Used for refractory complex partial seizures and infantile spasms.
• Ebixa – Treats dementia.
• Azilect – For Parkinson’s disease.
• Xenazine – Addresses chorea.
• Deanxit – Treats depression.
• Cipramil – For depression and anxiety.
• Cisordinol – Used for psychosis.

Pipeline Developments

• Eptinezumab – In phase 3 for migraine prevention and cluster headache.
• Lu AG09222 – Phase 2 trial for migraine prevention.
• Lu AG13909 – Phase 1 trial for neurohormonal dysfunctions.
• Brexpiprazole – Investigated for post-traumatic stress disorder.
• Lu AF28996 – Phase 1 trial for Parkinson’s disease.
• MAGLi Program – Phase 1 trial for neurology.
• Bexicaserin – Phase 3 trial for developmental and epileptic encephalopathies.
• Amlenetug – Phase 3 trial for synucleinopathies.
• Lu AG22515 – Phase 1 trial for neurology.

Founded in 1915, H. Lundbeck A/S remains committed to advancing treatments for complex brain disorders.